FindTrial
Sign In

Sym004

DRUG8 trials

Sponsors

Symphogen A/S, Merck KGaA, Darmstadt, Germany

Conditions

CarcinomaCarcinoma, Squamous Cell of Head and NeckColorectal Cancer MetastaticMetastatic Colorectal CancerSolid TumorsSquamous Non-Small Cell Lung Cancer

Phase 1

Sym004 in Patients With Advanced Solid Tumors
CompletedNCT01117428
Symphogen A/SMetastatic Colorectal Cancer
Start: 2010-03-31End: 2015-05-31Updated: 2018-10-15
Japanese Phase 1 Trial of Sym004 in Solid Tumors
CompletedNCT01955473
Merck KGaA, Darmstadt, GermanySolid Tumors
Start: 2013-10-31End: 2015-10-31Updated: 2017-08-23
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
TerminatedNCT02568046
Symphogen A/SMetastatic Colorectal Cancer
Start: 2016-03-15End: 2018-05-05Updated: 2019-03-26
Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
WithdrawnNCT02924233
Symphogen A/SSquamous Non-Small Cell Lung Cancer
Start: 2016-11-30End: 2017-02-28Updated: 2017-08-28

Phase 2

Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
CompletedNCT01417936
Symphogen A/SCarcinoma, Squamous Cell of Head and Neck
Start: 2011-07-31End: 2012-10-31Updated: 2018-10-15
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
WithdrawnNCT02965417
Symphogen A/SMetastatic Colorectal Cancer
Start: 2016-12-31End: 2017-01-31Updated: 2017-02-01
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
TerminatedNCT03549338
Symphogen A/SCarcinoma, Colorectal Cancer Metastatic, Metastatic Colorectal Cancer
Start: 2018-11-29End: 2019-03-09Updated: 2020-09-28

Phase 3

Sym004 Versus TAS-102 in Patients With mCRC
WithdrawnNCT03717038
Symphogen A/SCarcinoma, Colorectal Cancer Metastatic, Metastatic Colorectal Cancer
Start: 2019-02-28End: 2025-12-31Updated: 2019-02-04

Related Papers

Population pharmacokinetics (popPK) of Sym004 to evaluate the effect of intrinsic and extrinsic factors on exposure in metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology2019-01-29
Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors.
2018-09-2516 citations
Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors.
Journal of Clinical Oncology2016-05-201 citations
Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.
Journal of Clinical Oncology2014-05-202 citations